Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00276172 · ClinicalTrials.gov registry record · Phase 3
Open-Label Natalizumab Safety Extension Study
A Phase 3 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,615
- Enrollment target
NCT00276172 is a Phase 3 study that has completed, run by Biogen. The registered enrollment target is 1,615 participants.
The verdict
NCT00276172, a Phase 3 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,615 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the safety and the immunogenicity of extended treatment with natalizumab when administered at a dose of 300 mg intravenously (IV) to subjects with multiple sclerosis (MS) who have completed natalizumab Studies C-1801, C-1802, or C-1803.
Interventions
- DRUG Natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,615 participants |
| Start Date | 2003-12 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00276172
The ClinicalTrials.gov registry entry for NCT00276172 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,615 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Natalizumab is the first listed.
NCT00276172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00276172 about?
NCT00276172 is a clinical study titled "Open-Label Natalizumab Safety Extension Study". The primary objective of this study is to determine the safety and the immunogenicity of extended treatment with natalizumab when administered at a dose of 300 mg intravenously (IV) to subjects with multiple sclerosis (MS) who have completed natalizumab Studies C-1801, C-1802, or C-1803.
What is the current status of trial NCT00276172?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,615 participants. The study started on 2003-12. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00276172?
The interventions under investigation include: Natalizumab (DRUG).
Who is sponsoring clinical trial NCT00276172?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.